home / stock / anab / anab quote
Last: | $25.47 |
---|---|
Change Percent: | -0.53% |
Open: | $24.88 |
Close: | $25.47 |
High: | $25.98 |
Low: | $24.83 |
Volume: | 271,693 |
Last Trade Date Time: | 07/08/2024 03:00:00 am |
Quotes are delayed by 15 to 20 minutes.
Last | Open | Close | High | Low | Volume | Date |
---|---|---|---|---|---|---|
$25.47 | $24.88 | $25.47 | $25.98 | $24.83 | 271,693 | 07-08-2024 |
$24.75 | $24.9 | $24.75 | $25.04 | $24.39 | 148,546 | 07-05-2024 |
$24.9 | $24.59 | $24.9 | $25.45 | $24.31 | 281,290 | 07-04-2024 |
$24.9 | $24.59 | $24.9 | $25.45 | $24.31 | 281,290 | 07-03-2024 |
$23.94 | $24.42 | $23.94 | $24.76 | $23.72 | 249,252 | 07-02-2024 |
$24.61 | $25 | $24.61 | $25.3334 | $24.4 | 191,145 | 07-01-2024 |
$25.06 | $25 | $25.06 | $25.37 | $24.54 | 546,539 | 06-28-2024 |
$24.8 | $24.36 | $24.8 | $24.85 | $23.86 | 119,278 | 06-27-2024 |
$24.22 | $23.86 | $24.22 | $24.3 | $23.39 | 291,110 | 06-26-2024 |
$23.85 | $23.92 | $23.85 | $24.09 | $23.63 | 203,439 | 06-25-2024 |
$24.05 | $24.05 | $24.05 | $24.39 | $23.58 | 217,765 | 06-24-2024 |
$24 | $23.17 | $24 | $24.6167 | $23.17 | 1,223,996 | 06-21-2024 |
$22.89 | $22.97 | $22.89 | $23.3 | $22.26 | 479,252 | 06-20-2024 |
$22.89 | $23.16 | $22.89 | $23.16 | $22.36 | 322,144 | 06-19-2024 |
$22.89 | $23.16 | $22.89 | $23.16 | $22.36 | 322,144 | 06-18-2024 |
$23.38 | $23.81 | $23.38 | $23.93 | $22.87 | 181,939 | 06-17-2024 |
$23.77 | $24.01 | $23.77 | $24.07 | $23.48 | 155,791 | 06-14-2024 |
$24.25 | $23.98 | $24.25 | $24.55 | $23.71 | 193,034 | 06-13-2024 |
$24.1 | $24.15 | $24.1 | $24.93 | $23.64 | 480,591 | 06-12-2024 |
$23.65 | $23.43 | $23.65 | $24.4 | $22.94 | 433,142 | 06-11-2024 |
News, Short Squeeze, Breakout and More Instantly...
2024-05-10 18:15:02 ET Wells Fargo analyst issues BUY recommendation for ANAB on May 10, 2024 05:01PM ET. The previous analyst recommendation was Buy. ANAB was trading at $23.41 at issue of the analyst recommendation. The overall analyst consensus : HOLD. Current ana...
Enrollment ongoing for global Phase 2b trial to treat atopic dermatitis (AD) with ANB032, our BTLA agonist; reiterating top-line data anticipated by year-end 2024 Enrollment ongoing for global Phase 2b trial to treat rheumatoid arthritis (RA) and global Phase 2 trial to treat ulcerative colit...
All eight patients from GEMINI-1 who responded to a single intravenous (IV) imsidolimab dose and were subsequently re-randomized to monthly subcutaneous (SC) maintenance dosing of imsidolimab in GEMINI-2 through at least 24 weeks maintained clear to almost clear skin and none experienced a flare ...